1. Yoshihiro Komatsu
  2. Yuji Mishina  Is a corresponding author
  1. The University of Texas Medical School at Houston, United States
  2. University of Michigan, United States

The skull consists of several bony plates that are joined together at cranial sutures, and progenitor cells that reside in these sutures have a crucial role in supporting the rapid growth of new bone to accommodate the growing infant brain. However, in approximately 1 in 2500 babies the cranial sutures fuse together prematurely (either just before birth or shortly afterwards), resulting in a skull deformity known as craniosynostosis (Wilkie et al., 2010). In this condition, the bones of the skull cannot grow quickly enough to keep up with the growing brain, resulting in increased pressure inside the skull. If craniosynostosis is left untreated, it can result in a loss of vision, hearing problems and chronic headaches.

Although some cases of craniosynostosis have been linked to a number of genetic mutations, 70% of observed cases still have no known genetic cause (Twigg and Wilkie, 2015). A form of craniosynostosis called non-syndromic midline (metopic and sagittal) craniosynostosis accounts for half of all reported cases (Greenwood et al., 2014; Figure 1), but very few of these cases have been associated with genetic mutations. Now, in eLife, Richard Lifton and colleagues at Yale University School of Medicine and Craniosynostosis and Positional Plagiocephaly Support, Inc. – including Andrew Timberlake as first author – report that two genetic mutations, each of which has little impact on its own, can result in devastating outcomes when they are both present (Timberlake et al., 2016).

3D reconstructions of the skull shapes that result from two types of non-syndromic craniosynostosis.

Top row: In metopic craniosynostosis, the metopic suture that passes down the middle of the forehead fuses prematurely. This results in a narrow forehead that forms with a ridge down the suture. In an attempt to compensate, the skull grows in a way that pushes the forehead forward. Bottom row: sagittal craniosynostosis results from the premature fusion of the sagittal suture along the top of the skull. As a result, the skull stays narrow and extends toward the front and back to compensate.

Genome-wide association studies have identified several single nucleotide polymorphisms that are associated with non-syndromic midline craniosynostosis (Justice et al., 2012). The most significant of these mutations is located close to the gene for a bone morphogenetic protein (BMP) called BMP2, so this site might act as an enhancer to increase the production of BMP2 (Justice et al., 2012). BMP is known to be important in bone development (Urist, 1965), and previous studies have suggested that altered BMP signaling leads to craniosynostosis (Jabs et al., 1993).

It has been suggested that the sporadic occurrence of non-syndromic craniosynostosis is due to de novo (non-inherited) genetic mutations and/or because these mutations do not consistently produce the same symptoms. To identify genetic mutations associated with midline craniosynostosis, Timberlake et al. sequenced the whole exome (that is, the part of the genome formed by exons) of 191 people who were the first in their family to display the symptoms of non-syndromic midline craniosynostosis; they also sequenced the exomes of both parents of 132 of these volunteers. The sequences revealed a number of different de novo mutations in the gene that encodes SMAD6, a molecule that is known to inhibit BMP signaling. Most of the mutations prevent the SMAD6 protein from working.

Timberlake et al. found that SMAD6 mutations produce craniosynostosis in only 9% of cases. However, when an individual has both the SMAD6 mutation and the BMP2 risk allele (which on its own leads to the disorder in just 0.08% of cases), craniosynostosis occurs 100% of the time. Thus, these findings clearly indicate that epistatic interactions – interactions where the effect produced by a given gene depends on the presence of other genes – of rare (SMAD6) and common (BMP2) gene variants are a defining feature of the cause of midline craniosynostosis. As a result, these genetic mutations are likely to account for as many cases of craniosynostosis as the single mutation in a gene called FGFR2 that is currently known as the most frequent cause of craniosynostosis.

Timberlake et al. also show that there is no epistatic interaction between the mutant SMAD6 variant and the other mutation that is known to be associated with midline craniosynostosis (a single nucleotide polymorphism in BBS9; Justice et al., 2012). This finding further supports the hypothesis that an increase in BMP signaling is likely to underlie the symptoms of craniosynostosis.

BMPs can cause bone to form in abnormal places (Urist, 1965), so it is possible that the symptoms of craniosynostosis are caused by increased bone formation "filling in" the cranial suture and depleting the numbers of progenitor cells found there. Bone forms as a result of these osteoprogenitor cells developing into cells called osteoblasts, which secrete the materials that form bone. However, the story may not be so simple, because if increased BMP signaling occurs only in osteoblasts, mice do not develop the symptoms of craniosynostosis (Komatsu et al., 2013). Instead, an increased rate of cell death in the osteoprogenitor cell population seems to be the primary cause of craniosynostosis in mutant mice that exhibit excessive BMP signaling. To support this notion, mutant mice treated in the womb with drugs that prevent cell death do not develop skull deformities (Hayano et al., 2015). The obvious next steps are to understand the cellular mechanisms that cause cranial sutures to fuse prematurely, and to confirm whether human patients with mutations in the Smad6 and BMP2 genes experience increased cell death in the sutures.

At present the only option for treating craniosynostosis is repeated reconstructive surgery: however, the work of Timberlake et al. and other groups suggest that an alternative therapeutic approach could be to prevent cell death in sutures. Developing such an approach will require researchers to pool together all the knowledge that has been gained from a wide range of genetics studies in both mice and humans. This is therefore a crucial moment in the search for the best treatment strategy for a large proportion of people with non-syndromic craniosynostosis.

References

Article and author information

Author details

  1. Yoshihiro Komatsu

    Department of Pediatrics, The University of Texas Medical School at Houston, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Yuji Mishina

    Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, United States
    For correspondence
    mishina@umich.edu
    Competing interests
    The authors declare that no competing interests exist.

Publication history

  1. Version of Record published:

Copyright

© 2016, Komatsu et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,240
    views
  • 132
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yoshihiro Komatsu
  2. Yuji Mishina
(2016)
Craniosynostosis: An epistatic explanation
eLife 5:e21162.
https://doi.org/10.7554/eLife.21162

Further reading

    1. Chromosomes and Gene Expression
    2. Immunology and Inflammation
    Matthew C Pahl, Prabhat Sharma ... Andrew D Wells
    Research Article

    Genome-wide association studies (GWAS) have identified hundreds of genetic signals associated with autoimmune disease. The majority of these signals are located in non-coding regions and likely impact cis-regulatory elements (cRE). Because cRE function is dynamic across cell types and states, profiling the epigenetic status of cRE across physiological processes is necessary to characterize the molecular mechanisms by which autoimmune variants contribute to disease risk. We localized risk variants from 15 autoimmune GWAS to cRE active during TCR-CD28 co-stimulation of naïve human CD4+ T cells. To characterize how dynamic changes in gene expression correlate with cRE activity, we measured transcript levels, chromatin accessibility, and promoter–cRE contacts across three phases of naive CD4+ T cell activation using RNA-seq, ATAC-seq, and HiC. We identified ~1200 protein-coding genes physically connected to accessible disease-associated variants at 423 GWAS signals, at least one-third of which are dynamically regulated by activation. From these maps, we functionally validated a novel stretch of evolutionarily conserved intergenic enhancers whose activity is required for activation-induced IL2 gene expression in human and mouse, and is influenced by autoimmune-associated genetic variation. The set of genes implicated by this approach are enriched for genes controlling CD4+ T cell function and genes involved in human inborn errors of immunity, and we pharmacologically validated eight implicated genes as novel regulators of T cell activation. These studies directly show how autoimmune variants and the genes they regulate influence processes involved in CD4+ T cell proliferation and activation.

    1. Chromosomes and Gene Expression
    2. Developmental Biology
    Leif Benner, Savannah Muron ... Brian Oliver
    Research Article

    Differentiation of female germline stem cells into a mature oocyte includes the expression of RNAs and proteins that drive early embryonic development in Drosophila. We have little insight into what activates the expression of these maternal factors. One candidate is the zinc-finger protein OVO. OVO is required for female germline viability and has been shown to positively regulate its own expression, as well as a downstream target, ovarian tumor, by binding to the transcriptional start site (TSS). To find additional OVO targets in the female germline and further elucidate OVO’s role in oocyte development, we performed ChIP-seq to determine genome-wide OVO occupancy, as well as RNA-seq comparing hypomorphic and wild type rescue ovo alleles. OVO preferentially binds in close proximity to target TSSs genome-wide, is associated with open chromatin, transcriptionally active histone marks, and OVO-dependent expression. Motif enrichment analysis on OVO ChIP peaks identified a 5’-TAACNGT-3’ OVO DNA binding motif spatially enriched near TSSs. However, the OVO DNA binding motif does not exhibit precise motif spacing relative to the TSS characteristic of RNA polymerase II complex binding core promoter elements. Integrated genomics analysis showed that 525 genes that are bound and increase in expression downstream of OVO are known to be essential maternally expressed genes. These include genes involved in anterior/posterior/germ plasm specification (bcd, exu, swa, osk, nos, aub, pgc, gcl), egg activation (png, plu, gnu, wisp, C(3)g, mtrm), translational regulation (cup, orb, bru1, me31B), and vitelline membrane formation (fs(1)N, fs(1)M3, clos). This suggests that OVO is a master transcriptional regulator of oocyte development and is responsible for the expression of structural components of the egg as well as maternally provided RNAs that are required for early embryonic development.